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Synthesis and characterization of thiol-ending prodrugs and GNPs

Abacavir (ABC) derivative synthesis and abacavir-GNPs preparation
Protected abacavir conjugate: Abacavir (63 mg, 0.2 mmol) was dissolved in dry DMF (3 mL) followed by the addition of 11-(acetylthio)undecanoic acid (89 mg, 0.3 mmol) and DMAP (54 mg, 0.4 mmol). The solution was cooled to 0 ºC with an ice bath and EDC (84 mg, 0.4 mmol) was added. After 5 h the reaction was diluted with AcOEt and washed with water (4 × 5 mL). The organic phase was dried over Na 2 SO 4 and purified by column chromatography on silica gel (gradient MeOH/CH 2 Cl 2 1/20 to MeOH/CH 2 Cl 2 1/9) to obtain the protected abacavir derivative as a clear oil (100 mg, 0.12 mmol, 85% Abacavir derivative (ester prodrug): S-acetyl protected abacavir derivative (65 mg, 0.12 mmol) was dissolved in MeOH (3 mL) and stirred in presence of hydrazine acetate (35 mg, 0.3 mmol). After 24 h the reaction was diluted with AcOEt, neutralized with HCl (0.1 M) and washed with water (5 × 8 mL). The organic phase was dried over Na 2 SO 4 and the residue was purified by size-exclusion chromatography Sephadex LH-20 (MeOH/H 2 O 9/1) to give the unprotected abacavir derivative (34 mg, 56%). 
Lamivudine (3TC) derivative synthesis and lamivudine-GNPs preparation
Protected lamivudine derivative: Lamivudine (12 mg, 0.05 mmol) was dissolved in dry DMF (3 mL) followed by the addition of 11-(acetylthio)undecanoic acid (20 mg, 0.07 mmol) and DMAP (12.5 mg, 0.1 mmol). The solution was cooled to 0 ºC with an ice bath and EDC (19.5 mg, 0.1 mmol) was added. After 3 h the reaction was diluted with AcOEt and washed with water (4 × 5 mL). The organic phase was dried over Na 2 SO 4 and purified by column chromatography on silica gel (gradient MeOH/CH 2 Cl 2 1/40 to MeOH/CH 2 Cl 2 1/10) to obtain the protected lamivudine derivative as a clear oil (8 mg, 70%). Lamivudine derivative (ester prodrug): S-acetyl protected lamivudine derivative (4 mg, 0.007 mmol) was dissolved in MeOH (2 mL) and stirred in presence of hydrazine acetate (2 mg, 0.02 mmol). After 3 h the reaction was diluted with AcOEt, neutralized with HCl (0.1 M) and washed with water (4 × 4 mL). The organic phase was dried over Na 2 SO 4 and the residue was purified by size-exclusion chromatography Sephadex LH-20 (MeOH/H 2 O 9/1) to give the unprotected lamivudine derivative (2 mg, 56%). 
Calculation of drug-loading on GNPs.
The average MW of glucose-GNP is 37 KDa with an estimated molecular formula of Au 140 (C 11 H 21 O 6 S) 35 [1] . 1 mg of glucose-= ~ . 7 μ f = ~ . 4 μ of glucose. We considered that the 0.1 equiv (respect to glucose) of the drug derivatives were linked on the gold surface because we did not observe drug derivatives in the GNPs washings. Then, we assumed that 1 mg of drug-GNPs carries ~ . 4 μ of drugs.
From LCu μ / L f u -GNPs the drug concentration was ~200-300 nM (after GNPs treatment at pH 0 for several days). In more details, 2 mg of drug-GNPs were treated with 1 mL of HCl (1 M), and then diluted 1000 times; we found 0.2 nmol of drug after 1000 times dilution before LC-MS analysis. We f u . μ of drug in 1 mL of drug-GNPs solution (2 mg/mL). In conclusion we can estimate that 1 mg of drug-. μ of drug.
